Binge Eating Disorder Clinical Trial
Official title:
Integrative Cognitive-Affective Therapy for Binge Eating Disorder
Verified date | July 2020 |
Source | University of Minnesota |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of the study is to test a newly developed individual psychotherapy treatment for binge eating disorder in adults. This treatment is a type of individual psychotherapy called Integrative Cognitive-Affective Therapy (ICAT) that focuses on helping people change their behaviors, feelings, thoughts about themselves, and relationships. This new treatment is being compared to an existing treatment called Cognitive-Behavior Therapy-Guided Self Help (CBTgsh), which focuses on changing behavior patterns through the use of reading and homework assignments along with sessions with a therapist. The primary hypothesis of this investigation is that ICAT will be associated with greater reductions in binge eating at end of treatment and follow-up compared to CBTgsh.
Status | Completed |
Enrollment | 96 |
Est. completion date | August 2017 |
Est. primary completion date | August 2017 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 65 Years |
Eligibility |
Inclusion Criteria: - Binge eating disorder (DSM-5) Exclusion Criteria: - History of gastric bypass surgery - Medical condition acutely affecting eating and/or weight - Current medical and/or psychiatric instability (e.g., acute suicidality) - Psychosis and/or bipolar disorder - Severe cognitive impairment or developmental disability - Inability to read English - Current substance use disorder - Current participation in psychotherapy and/or commercial weight loss program - Change in dosage and/or frequency of psychotropic medication in the past 6 weeks - Pregnant or breast feeding - BMI < 21 |
Country | Name | City | State |
---|---|---|---|
United States | Neuropsychiatric Research Institute | Fargo | North Dakota |
United States | University of Minnesota | Minneapolis | Minnesota |
Lead Sponsor | Collaborator |
---|---|
University of Minnesota | Neuropsychiatric Research Institute, Fargo, North Dakota |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Binge Eating Episode Frequency (Eating Disorder Examination) | Frequency of binge eating as measured by the Eating Disorder Examination | 17 Weeks and 6-month Follow-up | |
Secondary | Global Eating Disorder Symptoms (EDE) | Global Eating Disorder Symptoms as measured by the Eating Disorder Examination | 17 Weeks and 6-month follow-up | |
Secondary | Symptoms of Depression (BDI) | Symptoms of Depression as measured by the Beck Depression Inventory | 17 Weeks and 6-month follow-up | |
Secondary | Symptoms of Anxiety (STAI) | Symptoms of Anxiety as measured by the State-Trait Anxiety Inventory | 17 Weeks and 6-month Follow-up | |
Secondary | Self-Esteem (RSEQ) | Self-esteem as measured by the Rosenberg Self-Esteem Questionnaire | 17 Weeks and 6-month Follow-up |
Status | Clinical Trial | Phase | |
---|---|---|---|
Withdrawn |
NCT02978742 -
Evaluating and Implementing a Smartphone Application Treatment Program for Bulimia Nervosa and Binge Eating Disorder
|
N/A | |
Recruiting |
NCT02659488 -
Lisdexamfetamine in Binge Eating Disorder (BED): fMRI Effects
|
Phase 2 | |
Completed |
NCT02659475 -
Phentermine/Topiramate Extended Release in Binge Eating Disorder (BED)
|
Phase 2 | |
Completed |
NCT00601653 -
Effectiveness of Cognitive Behavioral Therapy Plus Nutritional Counseling in Promoting Weight Loss in People With Binge Eating Disorder
|
N/A | |
Completed |
NCT02834299 -
Dialectical Behavior Therapy Guided Self-Help for Binge Eating Disorder
|
N/A | |
Completed |
NCT02553824 -
FDA Approved Medication to Reduce Binge Eating and/or Purging
|
Phase 1 | |
Completed |
NCT02564588 -
Dasotraline Binge Eating Disorder Study
|
Phase 2/Phase 3 | |
Completed |
NCT00307190 -
Hormone Release and Stomach Disturbances in People With Binge Eating Disorder
|
N/A | |
Completed |
NCT01718483 -
SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
|
Phase 3 | |
Completed |
NCT01718509 -
SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
|
Phase 3 | |
Completed |
NCT02503098 -
Optimizing a Smartphone Application for Individuals With Eating Disorders
|
N/A | |
Active, not recruiting |
NCT01837953 -
Stepped Care for Binge Eating Disorder: Predicting Response to Minimal Intervention in a Randomized Controlled Trial
|
N/A | |
Completed |
NCT01010789 -
Armodafinil in Binge Eating Disorder (BED)
|
Phase 3 | |
Completed |
NCT01098435 -
ALK33-101: A Study of RDC-0313 (ALKS 33) in Adults With Binge Eating Disorder
|
Phase 2 | |
Completed |
NCT01552759 -
Appetite Hormones in Binge Eating Disorder
|
N/A | |
Completed |
NCT00330655 -
An Open-Label Trial of Memantine in the Treatment of Binge Eating Disorder
|
Phase 4 | |
Completed |
NCT01291173 -
Forced-dose Titration of SPD489 in Adults With Binge Eating Disorder
|
Phase 2 | |
Completed |
NCT03107026 -
A Study to Evaluate a Drug (Dasotraline) on the Safety, Effectiveness and How Well the Body Tolerates it, in Adults With Moderate to Severe Binge Eating Disorder
|
Phase 3 | |
Completed |
NCT02079935 -
Treatment of Eating Disorders by Physical Activity and Nutrition Counseling
|
N/A | |
Completed |
NCT00277641 -
Lamotrigine in the Treatment of Binge Eating Disorder Associated With Obesity
|
Phase 3 |